insights_auto
Why is ALNY up 5.36%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$165.04
arrow_upward
+5.36%(+8.39) 1D
$165.91
arrow_upward
+0.53% (+0.87)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$159.17
High
$168.35
Low
$158.82
Mkt. cap
22.11B
Avg. vol.
2.53M
Volume
3.59M
P/E ratio
8.36
52-wk high
$479.79
52-wk low
$149.18
EPS
$19.75
Beta
0.42
Shares outstanding
133.94M
No. of employees
2K
Open
$159.17
High
$168.35
Low
$158.82
Mkt. cap
22.11B
Avg. vol.
2.53M
Volume
3.59M
P/E ratio
8.36
52-wk high
$479.79
52-wk low
$149.18
EPS
$19.75
Beta
0.42
Shares outstanding
133.94M
No. of employees
2K
News stories
From web sources and news partners
Traders Union
·
11 hours ago
Alnylam Pharmaceuticals shares jump around 5.5% as strong Q3 product revenue drives commercial momentum
Moomoo
·
13 hours ago
Unusual Options Activity: ALNY, PEP and Others Attract Market Bets, ALNY V/OI Ratio Reaches 431.9
Trefis
·
1 day ago
What Moved Alnylam Stock?
BioPharma Dive
·
1 week ago
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealnylam.com